Detalhe da pesquisa
1.
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.
BMC Cancer
; 16: 135, 2016 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26906039
2.
Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
Cancer Metastasis Rev
; 31 Suppl 1: S19-27, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22821550
3.
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
Clin Genitourin Cancer
; 20(1): 25-34, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34789409
4.
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Clin Transl Oncol
; 10(10): 646-53, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18940745
5.
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Eur J Cancer
; 75: 73-82, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28222309
6.
Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer.
Breast J
; 14(5): 506-7, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18705667